Inactive Instrument

Metsera, Inc.

Stocks

Published on 09/22/2025 at 10:20 am EDT - Modified on 09/30/2025 at 05:34 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, everyone, and welcome to Pfizer's Analyst and Investor Call to discuss proposed acquisition of Metsera. Today's call is being recorded. At

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Full unlimited browsing across the entire site

Access to all the news and all the data

Access to US, EUROPE AND ASIA Portfolios

Zero Ads for a completely uninterrupted reading experience

Pro Tools: Expert insights, Expert Screeners, historical financial data and reports, thematic lists, transcripts...

12-12	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
12-08	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
11-25	Novo Nordisk Drug Helps Patients Lose Weight, Lower Blood Sugar in Trial -- Update	DJ
11-25	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
11-25	No plane sailing for Novo Nordisk
11-24	Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer's Trials -- Update	DJ
11-20	Major deals involving U.S. drugmakers and biotechs over the past decade	RE
11-18	Pfizer Seeks to Raise $5 Billion in Bond Sale for Metsera Deal	MT
11-18	Pfizer Seeking at Least $5 Billion in Bond Sale for Metsera Deal	MT
11-18	Pfizer Seeking at Least $5 Billion in Bond Sale for Metsera Deal, Bloomberg Reports	MT
11-16	Metsera, Inc.(NasdaqGS:MTSR) dropped from S&P Global BMI Index	CI
11-16	Metsera, Inc.(NasdaqGS:MTSR) dropped from S&P Biotechnology Select Industry Index	CI
11-16	Metsera, Inc.(NasdaqGS:MTSR) dropped from S&P TMI Index	CI
11-14	Uncertainty Spreads Faster Than Data
11-13	Metsera, Inc.(NasdaqGS:MTSR) dropped from Russell 2000 Index	CI

Duration

Period

Sector